As of November 10, 2026, Bicara Therapeutics Inc. is a publicly traded company (Nasdaq: BCAX). The largest holder reporting an active stake on Schedule 13D is RA Capital, at 11.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Vestal Point Capital, LP (8.3%), Deep Track Capital (6.21%), BlackRock (5.4%) (Schedule 13D/A, March 2, 2026).
Is this your company?
About to sign with, pay or invest in Bicara Therapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Bicara Therapeutics Inc. a real, registered company?
- Bicara Therapeutics Inc. files with the SEC under CIK 2023658 (its SEC filings).
- Its shares are listed under the ticker BCAX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under BICARA THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-07-27).
Who are Bicara Therapeutics Inc.'s owners and officers?
Bicara Therapeutics Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-07).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-07 | T. Rowe Price Investment Management, Inc. | 4.2% |
| Schedule 13G/A, 2026-08-13 | Janus Henderson Group LTD. | 4.8% |
| Schedule 13G, 2026-07-27 | Blackrock, Inc. | 5.4% |
| Schedule 13G, 2026-05-15 | Janus Henderson Group PLC | 5.1% |
| Schedule 13G/A, 2026-05-15 | Deep Track Capital, LP | 6.21% |
| Schedule 13G/A, 2026-05-15 | Vestal Point Capital, LP | 8.3% |
| Schedule 13G/A, 2026-05-08 | Red Tree Gp, LLC | 4.8% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 3.2% |
| Schedule 13G/A, 2026-04-08 | T. Rowe Price Investment Management, Inc. | 10.1% |
| Schedule 13D/A, 2026-03-02 | Ra Capital Management, L.P. | 11.5% |
| Schedule 13G, 2026-02-17 | T. Rowe Price Investment Management, Inc. | 5.9% |
| Schedule 13G/A, 2026-02-17 | Vestal Point Capital, LP | 6.5% |
Questions about who owns Bicara Therapeutics Inc.
Who owns Bicara Therapeutics Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Bicara Therapeutics Inc.: Ra Capital Management, L.P. (11.5%, Schedule 13D/A, filed 2026-03-02), Vestal Point Capital, LP (8.3%, Schedule 13G/A, filed 2026-05-15), Deep Track Capital, LP (6.21%, Schedule 13G/A, filed 2026-05-15), Blackrock, Inc. (5.4%, Schedule 13G, filed 2026-07-27) and Janus Henderson Group PLC (5.1%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of Bicara Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Bicara Therapeutics Inc. on this page are Ra Capital Management, L.P. (11.5%), Vestal Point Capital, LP (8.3%) and Deep Track Capital, LP (6.21%).
When did Ra Capital Management, L.P. buy into Bicara Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13D/A, filed 2026-03-02, reporting 11.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Bicara Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Bicara Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bicara Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Bicara Therapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- RA Capital Nexus Fund III, L.P., a director: 4,603,418 shares (6.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-03-02).
- RA Capital, a director and 10% owner: 4,603,418 shares (6.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-03-02).
- , a director and 10% owner: 4,603,418 shares (6.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-03-02).
- , a director and 10% owner: 4,603,418 shares (6.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-03-02).
- RA Capital Healthcare Fund LP, a director and 10% owner: 4,603,418 shares (6.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-03-02).
Shares outstanding: 66,387,197 as of 2026-11-03, from the company's latest SEC cover page.
How much has Bicara Therapeutics Inc. raised?
Latest IPO step: Bicara Therapeutics Inc. filed its final IPO prospectus (424B4, 2024-09-13).
IPO filings: 424B4, 2024-09-13, S-1/A, 2024-09-11, S-1/A, 2024-09-06, S-1/A, 2024-09-03, S-1, 2024-08-22.
Keep reading
More on Bicara Therapeutics Inc. and the records around it.
Bicara Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/bicara-therapeutics